Compare FUNC & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | FUNC | SGMT |
|---|---|---|
| Founded | 1900 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 247.8M | 238.7M |
| IPO Year | N/A | 2023 |
| Metric | FUNC | SGMT |
|---|---|---|
| Price | $38.62 | $6.39 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $29.75 |
| AVG Volume (30 Days) | 16.7K | ★ 500.1K |
| Earning Date | 10-20-2025 | 11-13-2025 |
| Dividend Yield | ★ 2.72% | N/A |
| EPS Growth | ★ 56.67 | N/A |
| EPS | ★ 3.84 | N/A |
| Revenue | ★ $83,662,000.00 | N/A |
| Revenue This Year | $16.22 | N/A |
| Revenue Next Year | $7.42 | N/A |
| P/E Ratio | $9.94 | ★ N/A |
| Revenue Growth | ★ 17.79 | N/A |
| 52 Week Low | $24.66 | $1.73 |
| 52 Week High | $42.50 | $11.41 |
| Indicator | FUNC | SGMT |
|---|---|---|
| Relative Strength Index (RSI) | 66.28 | 39.03 |
| Support Level | $37.74 | $6.02 |
| Resistance Level | $38.69 | $7.29 |
| Average True Range (ATR) | 0.73 | 0.55 |
| MACD | 0.26 | -0.15 |
| Stochastic Oscillator | 95.72 | 14.85 |
First United Corp is active in the financial services domain. The scope of its offering includes checking, savings, money market deposit accounts and certificates of deposit, business loans, personal loans, mortgage loans and lines of credit extended to both individuals and businesses. The bank also provides residential real estate construction loans to builders and individuals for single-family dwellings. The company's reportable operating segments include community banking and wealth management. The company generates the majority of its revenue from the Community Banking segment, which is engaged in delivering financial products and services, including various loan and deposit products, to consumer, business, and not-for-profit customers.
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.